- Home
- RAYA vs APVO Comparison
RAYA vs APVO Comparison
Compare RAYA & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAYA
- APVO
- Stock Information
- Founded
- RAYA 2019
- APVO 2016
- Country
- RAYA China
- APVO United States
- Employees
- RAYA N/A
- APVO N/A
- Industry
- RAYA Metal Fabrications
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- RAYA Consumer Discretionary
- APVO Health Care
- Exchange
- RAYA Nasdaq
- APVO Nasdaq
- Market Cap
- RAYA 6.1M
- APVO 4.9M
- IPO Year
- RAYA 2022
- APVO N/A
- Fundamental
- Price
- RAYA $5.73
- APVO $1.71
- Analyst Decision
- RAYA
- APVO
- Analyst Count
- RAYA 0
- APVO 0
- Target Price
- RAYA N/A
- APVO N/A
- AVG Volume (30 Days)
- RAYA 378.3K
- APVO 16.7M
- Earning Date
- RAYA 01-01-0001
- APVO 11-06-2025
- Dividend Yield
- RAYA N/A
- APVO N/A
- EPS Growth
- RAYA N/A
- APVO N/A
- EPS
- RAYA N/A
- APVO N/A
- Revenue
- RAYA $30,300,360.00
- APVO N/A
- Revenue This Year
- RAYA $20.95
- APVO N/A
- Revenue Next Year
- RAYA N/A
- APVO N/A
- P/E Ratio
- RAYA N/A
- APVO N/A
- Revenue Growth
- RAYA 49.10
- APVO N/A
- 52 Week Low
- RAYA $3.65
- APVO $1.32
- 52 Week High
- RAYA $737.00
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- RAYA 64.23
- APVO 52.17
- Support Level
- RAYA $3.65
- APVO $1.41
- Resistance Level
- RAYA $5.80
- APVO $1.98
- Average True Range (ATR)
- RAYA 0.71
- APVO 0.13
- MACD
- RAYA 0.39
- APVO 0.05
- Stochastic Oscillator
- RAYA 50.16
- APVO 62.31
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.